lenalidomide / Generic mfg. - LARVOL DELTA

Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma (ASH 2024) - P1 | "Median prior lines of therapy was 3 (range 2–12), 18 (38%) pts received prior lenalidomide–based therapy, 7 (15%) pts received prior chimeric antigen receptor T-cell therapy (CAR-T), and 4 (9%) received prior CD20 TCE therapy. The exposure-response analysis supports the target dose of 7.2 mg. Further studies of AZD0486 are planned as monotherapy and in combination regimens."

Clinical • Minimal residual disease • Residual disease • Diabetes • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P3 | N=358 | Recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

Front-line systemic treatment outcomes in POEMS syndrome. (PubMed, Br J Haematol) - "Questions remain regarding the use of induction therapy, given the known efficacy of melphalan autologous stem cell transplant (ASCT), as well as the optimal management of transplant-ineligible patients...Median PFS for this cohort was 5.6 years, with 5- and 10-year PFS of 57.2% and 31.8% respectively. Attainment of complete vascular endothelial growth factor (p < 0.001) and/or haematological response (p = 0.01) following front-line therapy was associated with a lower risk of relapse."

Journal • Endocrine Disorders • Hematological Disorders • Pain • Rare Diseases • Transplantation

A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degrader. (PubMed, Nat Commun) - "Immunomodulatory imide drugs (IMiDs) like lenalidomide and pomalidomide are effective in treating multiple myeloma (MM) but pose hematotoxicity risks by degrading neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3). Moreover, we have identified a CRBN ligand that mitigates these safety liabilities and can be effectively incorporated into PROTACs. This advancement provides a promising path toward safer preclinical development of PROTACs, especially as the field expands into chronic disease treatments beyond oncology."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • Targeted Protein Degradation • CRBN • IKZF1 • IKZF3

Natural product PROTACylation: Development of Maslinic acid-based JAK2 degraders for cancer therapy. (PubMed, Fitoterapia) - "Competitive inhibition experiments using excess MA or lenalidomide, along with MLN4924 treatment, validated the requirement for ternary complex formation and cullin-RING E3 ligase pathway dependence. P4 effectively downregulates the IL-6/JAK2/STAT3 signaling axis and simultaneously activates dual apoptotic pathways: intrinsic mitochondrial apoptosis (decreased Bcl-2, XIAP, survivin; increased Bax, cytochrome c, cleaved caspases) and ER stress-mediated apoptosis (elevated IRE1, BIP, ATF4, CHOP, p-JNK1, cleaved caspase-12). This work establishes P4 as a promising JAK2-targeting degrader whose anticancer efficacy derives from coordinated target elimination, oncogenic pathway suppression, and dual apoptotic pathway activation, validating natural product PROTACylation as a viable strategy for developing multifunctional anticancer therapeutics."

Journal • Oncology • Targeted Protein Degradation • ATF4 • BCL2 • BIRC5 • CASP12 • CRBN • ERN1 • IL6 • JAK2 • MAPK8 • XIAP

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (PubMed, N Engl J Med) - P3 | "The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, 2018-002992-16.)."

Journal • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Oncology • Thrombocytopenia • Transplantation

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial (ASH 2024) - "Of patients who achieved MRD-negativity (10–5) with D-VRd, >80% were alive and progression-free at 54 months. These data further support the use of D-VRd as a new standard of care for patients with NDMM that are TIE or for whom transplant is deferred."

Clinical • Minimal residual disease • P3 data • Residual disease • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial. (ASCO 2025) - P2 | "In this large randomized, multicenter investigator-initiated trial for NDMM, treatment with DKRd (59%) compared to KRd (36%) showed a significant, 2.5-fold higher MRD negativity rate with no new safety concerns. Updated EFS, PFS and OS results will be presented at the meeting. Based on these results, DKRd should be a new standard for most NDMM patients receiving initial KRd-backbone therapy."

Clinical • Acute Kidney Injury • Back Pain • Cardiovascular • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Musculoskeletal Diseases • Musculoskeletal Pain • Nephrology • Neutropenia • Novel Coronavirus Disease • Oncology • Orthopedics • Pain • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases • Septic Shock

MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial. (ASCO 2025) - P3 | "Funded by No funding sources reported Clinical Trial Registration Number: NCT04934475 Background: The phase III IFM2020-02-MIDAS study (NCT04934475) evaluated a minimal residual disease (MRD)-driven consolidation and maintenance strategy following induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRD) in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM)...MRD-positive patients after induction (MRD ≥10⁻⁵) were randomized to either single ASCT plus 2 cycles of IsaKRD (Arm C) or tandem ASCT (Arm D) followed by isatuximab plus iberdomide maintenance... After 6 induction cycles with IsaKRD, in patients who achieved MRD negativity at 10⁻⁵, MRD negativity rates at 10⁻⁶ before maintenance were not significantly different between the transplant-based approach and IsaKRD consolidation alone, whereas in patients who do not achieve MRD negativity at 10-5, tandem ASCT did not significantly improve MRD negativity rates at 10⁻⁶..."

P3 data • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post-hoc analysis of BENEFIT. (PubMed, J Thromb Haemost) - P3 | "In summary, the cumulative incidence of VTE remains high in patients with TI nMM. DOACs could be the most effective option for preventing VTE."

Journal • Retrospective data • Cardiovascular • Hematological Malignancies • Multiple Myeloma • Oncology • Renal Disease • Transplantation • Venous Thromboembolism

Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma. (PubMed, Blood) - P1/2 | "We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE® NHL-2 (phase 1b/2; NCT04663347). CRS events were mostly low grade (38% G1, 11% G2, 2% G3), all resolved, and none led to epcoritamab discontinuation. Fixed-duration epcoritamab plus R2 demonstrated deep, durable responses with manageable safety and favorable outcomes in R/R FL, irrespective of risk features."

Journal • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Novel Coronavirus Disease • Oncology

BCMA CAR T-Cell Therapy in Newly Diagnosed Primary Plasma Cell Leukemia Ineligible for Transplantation: An Open Label, Single-arm, Phase 2 Study (CAREMM-002) (IMS 2025) - P2 | "After 3ŌĆō4 cycles of VRd-based induction treatment, patients received lymphodepletion and a single infusion of BCMA CAR-T cells (3├Ś10ŌüČ cells/kg), followed by consolidation and lenalidomide maintenance... Frontline BCMA CAR-T therapy demonstrated unprecedented depth and durability of response with manageable safety in transplant-ineligible PPCL patients-a population with historically dismal outcomes and limited therapeutic options."

CAR T-Cell Therapy • Clinical • P2 data • Anemia • Hematological Disorders • Hematological Malignancies • Leukemia • Leukopenia • Neutropenia • Plasma Cell Leukemia • Plasmacytoma • Thrombocytopenia • Transplantation

Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study (ASH 2025) - P1, P1/2 | "Arm A evaluated etentamig in combination with POM+DEX in pts after≥3 prior lines of therapy (LoT), including the IMiD lenalidomide, a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody (mAB). Preliminary data are promising and suggest etentamig in combination with POM+DEX istolerable with robust efficacy (ORR and ≥VGPR: 81% and 72%, respectively) in pts with ≥3 prior LoT(median LoT = 4). In this heavily pretreated population, median PFS was not reached with a median followup of 18 months, suggesting prolonged disease control with etentamig in combination with POM+DEX.Overall, these data support further exploration of the regimen in a randomized Phase 3 study."

Clinical • Combination therapy • P1 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Influenza • Multiple Myeloma • Neutropenia • Pneumonia • Renal Disease • Respiratory Diseases

Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND) (ASH 2025) - P3 | "Introduction:Selinexor (S) is an oral selective exportin 1 inhibitor approved in relapsed multiple myeloma (MM) incombination with bortezomib (V) and dexamethasone (d)...Patients received ondansetron 8mg immediately prior to, and 8-hours following each S dose.Additional ondansetron and low-dose olanzapine were used as required for break-through nausea andvomiting...In this randomized phase III study, the addition of low-dose S to R maintenance following ASCT did notresult in a significant PFS benefit compared to R alone in NDMM. Although a higher CR rate was observedwith SR, this came at the cost of increased toxicity, including more infections, cytopenias andgastrointestinal AEs. Quality of life, as assessed by EORTC QLQ-C30 and MY20, was comparable betweenarms."

Clinical • P3 data • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • Transplantation • XPO1

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results (ASH 2025) - P1/2, P3 | "Median number of prior treatments was 4.5 (range, 2–6) in Part A and 3 (range, 1–12)in Part B Cohort D. Approximately one-third of the treated patients were exposed to prior T-cell–redirecting therapy, approximately one-third had prior lenalidomide (len) exposure, and approximatelyone-third were refractory to the last regimen received. A higher ORR/CRR and similar tolerability were observed with GOLCA 0.4 mg + R vsGOLCA 0.2 mg + R, including in patients with prior len-based and/or T-cell–redirecting treatment. Thesedata support continued development of GOLCA 0.4 mg + R as a fixed-duration, chemotherapy-free,outpatient option in the ongoing Phase 3 GOLSEEK-4 study in 2L+ FL (NCT06911502)."

Clinical • P1/2 data • Cardiovascular • Febrile Neutropenia • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Lymphoma • Neutropenia • Pulmonary Embolism • Respiratory Diseases • CRBN • IKZF1

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma (ASH 2025) - P2 | "Background : First-line therapy for newly diagnosed large B-cell lymphoma (LBCL) has remainedchemotherapy-based for nearly five decades, with only incremental advances such as the addition ofrituximab and polatuzumab vedotin. The Smart Stop trial establishes that reducing or removing chemotherapy is feasible inpatients with newly diagnosed LBCL who achieve a complete response after targeted therapy, withoutcompromising curative potential. The combination of lenalidomide, tafasitamab, rituximab, andacalabrutinib is highly effective as an initial chemotherapy-free combination in patients with newlydiagnosed LBCL. Time to event data and ctDNA analysis will be updated for presentation at the meeting.Further trials are warranted to explore the Smart Stop approach in multicenter randomized trials, andadditional combinations are planned."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05) (ASH 2025) - P3 | "The BENEFIT study continues to support the efficacy of the quadruplet Isa-VRd regimen inNDMM TI patients, notably through improved sustained MRD negativity rates. These data support Isa-VRdas a new standard of care (SOC) for NDMM TI patients aged 65–79 years, including those with HRMM.ClinicalTrials.gov Identifier: NCT04751877"

Minimal residual disease • P3 data • Residual disease • Hematological Malignancies • Multiple Myeloma • Transplantation

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. (PubMed, Lancet) - P3 | "Epcoritamab plus R2 resulted in significantly higher response rate and longer progression-free survival versus R2 among participants with follicular lymphoma who had received at least one line of therapy. Epcoritamab plus R2 had more grade 3 or higher adverse events versus R2. Adverse events were manageable and consistent with the established safety profiles of the individual components, with no new safety findings identified. These findings position epcoritamab plus R2 as a new standard of care for second-line or subsequent treatment of follicular lymphoma."

Journal • P3 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. (PubMed, Lancet) - P3 | "The addition of tafasitamab to lenalidomide and rituximab resulted in a statistically significant and clinically meaningful improvement in progression-free survival, with an acceptable safety profile in patients with relapsed or refractory follicular lymphoma. This combination represents a potential new standard-of-care treatment."

Journal • P3 data • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Oncology

Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial. (PubMed, Lancet Haematol) - P1/2 | "In patients with Richter transformation, epcoritamab monotherapy showed clinically meaningful antitumour activity, although the investigator-assessed overall response rate was below the alternative hypothesis of 50%, with a safety profile consistent with previous studies. These findings support further investigation of epcoritamab as a potential treatment option for patients with Richter transformation."

Journal • Monotherapy • P1/2 data • B Cell Lymphoma • Cardiovascular • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Richter's Syndrome • Septic Shock • Small Lymphocytic Lymphoma • Thrombocytopenia • TP53

MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma. (PubMed, Blood Adv) - P2 | "Longitudinal cfDNA analysis in ALR revealed clonal evolution during response and progression. This safe and active regimen is feasible as a time-limited initial therapy for MCL patients and warrants further evaluation in response-adapted strategy."

Journal • Fatigue • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Thrombocytopenia • TP53

Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001). (PubMed, J Clin Oncol) - P2 | "Frontline BCMA CAR-T therapy induces deep, rapid, and durable remissions with a manageable safety profile in the NDMM population ineligible for or not proceeding to ASCT. These findings support its investigation as a potentially practice-changing strategy for this population."

Journal • P2 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Leukopenia • Multiple Myeloma • Neutropenia • Oncology • Thrombocytopenia • Transplantation

Lessons from the IELSG45 trial: The impact of patient fitness on dropout rate in primary central nervous system lymphoma (PCNSL) studies (ASH 2025) - "Patients deemed adequately fit were assigned to receive the standard combination of HDMTX,procarbazine, and rituximab as induction therapy...Patients ineligible for HDMTX wereassigned to receive concomitant whole-brain radiotherapy, temozolomide, and rituximab as inductiontherapy, followed by maintenance temozolomide (Part B)...The 3-year OS was 44 (±16%) forprocarbazine and 54 (±14%) for lenalidomide... Risk of treatment failure (in terms of dropout and survival rates) appeared higher comparedto the PRIMAIN trial. Discrepancies in feasibility and efficacy between PRIMAIN and FIORELLA trialsgenerate some concerns about generalization of results of PCNSL trials among different geographicalregions.These unexpected outcomes offer several valuable lessons on the incorporation of comorbidity indexesinto trial eligibility/stratification and the relevance of interim analyses to inform ethical decisions early."

Clinical • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Subarachnoid Hemorrhage

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter Study. (PubMed, Asia Pac J Clin Oncol) - "This study demonstrates that real-world outcomes of weekly RVD regimens have comparable efficacy to published twice-weekly regimens; however, toxicity remains a significant challenge in this patient population."

Clinical • Journal • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Oncology • Pain • Transplantation

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL (clinicaltrials.gov) - P2 | N=145 | Recruiting | Sponsor: Ruijin Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20